NEW YORK, Aug. 24 (GenomeWeb News) - Icoria will identify biomarkers of toxicity in animal models for Isis Pharmaceuticals, the biotechnology company said yesterday.

Icoria will use its metabolomics platform to evaluate differences in treated and untreated animal subjects to identify biomarkers that Isis will use to suggest pathways for alteration by potential drug candidates, Icoria said.

Financial details were not disclosed.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The Chan Zuckerberg Initiative is investing in Cold Spring Harbor Laboratory's BioRxiv.

A study appearing in PLOS One finds that shortened consent forms don't affect clinical trial participants' understanding of the study.

The National Security Agency monitored signal intelligence for signs of "nefarious" genetic engineering projects, Gizmodo reports.

In Nature this week: barley genome sequenced, method for genotyping and phasing short tandem repeats, and more.